Page 9 - Sohini Das

Rare earth crisis: Indian companies hopeful as global panic sets in

With China tightening rare earth exports, Indian firms eye domestic incentives and stockpiling, as global automakers and medical device makers face rising supply fears

Wockhardt's novel antibiotic Zaynich eyes $9 billion global market

Company to launch Zaynich in India this fiscal; sees $7 bn market in US and EU and ₹17,000 crore in India; USFDA, EU filings underway for FY26

Bangladesh unrest cuts India's medical tourism revenue by up to 35%

India sees sharp fall in Bangladeshi medical tourists in FY25 as regime change and visa curbs hurt Apollo and Manipal revenues; recovery expected only by FY26

Harrier.ev in driver's seat as Tata Motors eyes 50% market share in EVs

Electric PV market expected to grow by over 50% in FY26; company yet to disclose full price range of Harrier EV

Tata Motors bets on Altroz to 2x market share in premium hatchbacks

The 25,000-30,000 units a month premium hatchback segment accounts for nearly 6-7 per cent of passenger vehicle (PV) sales, and is dominated by models like Baleno of Maruti Suzuki

Bharat Biotech's oral cholera vaccine Hillchol clears phase 3 trials

In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years

Entry-level car buyers priced out even as SUV sales surge in India

Two-wheeler owners finding upward mobility challenging

Torrent Pharma Q4 PAT up 11% on strong India biz; Aman Mehta named MD

Torrent Pharma posts Rs 498 crore PAT in Q4FY25; Aman Mehta to become MD from August 1 as part of long-term strategic succession planning by the board

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Passenger vehicles sales up 4% in April, two-wheeler despatches fall

Overall exports up 20% in April amid geopolitical tensions, says SIAM

Piramal Pharma expects single-digit growth in FY26 amid uncertainties

PPL projects a muted FY26 due to global headwinds but aims to double its India consumer health business turnover to Rs 2,000 crore by FY30 through scale and expansion

Tata Motors Q4FY25 profit drops 51%, flags challenges amid tariff war

Deferred tax gain and exceptional costs dent Q4 profit for Tata Motors, though FY25 revenue and PBT hit record highs amid global challenges and tariff uncertainties

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

US President Donald Trump's drug price slash could sting Indian pharma

Up to 80% US price cuts may squeeze margins, push up innovator drug costs

Dr Reddy's Q4 results: Profit rises 22% to ₹1,594 crore on record revenue

Dr Reddy's posts highest-ever quarterly revenue and profit in Q4 FY25 with strong growth in generics, PSAI and NRT acquisition; FY25 PAT up 2 per cent at ₹5,654 crore

Mercedes-Benz India focuses on deep localisation as forex hit push costs up

Luxury carmaker to raise prices in two phases in 2025 due to forex pressures while expanding localisation to protect margins and banking on India's economic resilience

Boost to Jaguar Land Rover: US trade deal cuts duty to 10% for 100K UK cars

JLR had paused shipments to the US in April following US' declaration of a 25 per cent tariff on automobile imports

India-UK FTA: Automobile stocks up after the signing of trade deal

The auto-component industry which exports around $757 mn worth of parts to that country may benefit from the trade deal

Trump's 'Make in America' push: Indian drug cos in no rush to make US shift

Pharma industry veteran said that the US wanting to encourage local production is a very natural thing to do

Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr

India branded business grows 8% in Q4FY25 with 4 product launches while Ex-US markets rise 43% and US segment delivers 20% growth during the quarter